Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Integrated Community Oncology Network, LLC
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cancer Center or Florida
mi
from
Ocoee, FL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cancer Center or Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Peachtree Hematology/Oncology
mi
from
Atlanta, GA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Peachtree Hematology/Oncology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Georgia Cancer Specialists
mi
from
Tucker, GA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Georgia Cancer Specialists
mi
from
Tucker, GA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Rush University Medical Center
mi
from
Chicago, IL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Univ of Illinois
mi
from
Chicago, IL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cancer Care Specialists of Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cancer Institute at Alexian Brothers
mi
from
Elk Grove Village, IL
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cancer Institute at Alexian Brothers
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Indiana Oncology Hematology Consultants
mi
from
Indianapolis, IN
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Indiana Oncology Hematology Consultants
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Hematology Oncology of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Kansas City Cancer Center, LLC
mi
from
Overland Park, KA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Louisville Oncology
mi
from
Louisville, KY
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Louisville Oncology
mi
from
Louisville, KY
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Hematology-Oncology Clinic
mi
from
Baton Rouge, LA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Hematology-Oncology Clinic
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Frederick Memorial Hospital
mi
from
Frederick, MD
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Frederick Memorial Hospital
mi
from
Frederick, MD
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Tuffs-New England Medical Center
mi
from
Boston, MA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Tuffs-New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Henry Ford Health Systems
mi
from
Detroit, MI
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Henry Ford Health Systems
mi
from
Detroit, MI
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
West Michigan Regional Cancer and Blood Center
mi
from
Free Soil, MI
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
West Michigan Regional Cancer and Blood Center
mi
from
Free Soil, MI
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
University of Missouri
mi
from
Columbia, MO
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
University of Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Deaconess Billings Clinic
mi
from
Billings, MT
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Deaconess Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
New York Oncology
mi
from
Albany, NY
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
New York Oncology
mi
from
Albany, NY
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Presbyterian Hospital Cancer Center
mi
from
Charlotte, NC
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Presbyterian Hospital Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Dayton Oncology And Hematology
mi
from
Kettering, OH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Dayton Oncology And Hematology
mi
from
Kettering, OH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Providence Portland Medical Center
mi
from
Portland, OR
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Hematology and Oncology Associates of NEPA
mi
from
Dunmore, PA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Hematology and Oncology Associates of NEPA
mi
from
Dunmore, PA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Mary Crowley Research Center
mi
from
Dallas, TX
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Mary Crowley Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Tyler Cancer Center
mi
from
Tyler, TX
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Rainer Oncology Professional Services
mi
from
Puyallup, WA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Rainer Oncology Professional Services
mi
from
Puyallup, WA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cancer Care Northwest
mi
from
Spokane, WA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
University of Wisconsin
mi
from
Madison, WI
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
mi
from
Linz,
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
mi
from
Linz,
Click here to add this to my saved trials
Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial
Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial
Status: Enrolling
Updated:  4/5/2018
University of California at San Francisco
mi
from
San Francisco, CA
Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial
Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial
Status: Enrolling
Updated: 4/5/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Hematopoetic Stem Cell Transplant and Physical Function
Effects of a Multidirectional Walking Program on Physical Function and Quality of Life in Hematopoetic Stem Cell Transplant Patients
Status: Enrolling
Updated:  4/5/2018
Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Hematopoetic Stem Cell Transplant and Physical Function
Effects of a Multidirectional Walking Program on Physical Function and Quality of Life in Hematopoetic Stem Cell Transplant Patients
Status: Enrolling
Updated: 4/5/2018
Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
CHI Saint Vincent Cancer Center Hot Springs
mi
from
Hot Springs, AR
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
CHI Saint Vincent Cancer Center Hot Springs
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Epic Care-Dublin
mi
from
Dublin, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Epic Care-Dublin
mi
from
Dublin, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Bay Area Breast Surgeons, Incorporated
mi
from
Emeryville, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Bay Area Breast Surgeons, Incorporated
mi
from
Emeryville, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Epic Care Partners in Cancer Care
mi
from
Emeryville, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Epic Care Partners in Cancer Care
mi
from
Emeryville, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated:  4/6/2018
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients With Multiple Ipsilateral Breast Cancers (MIBC)
Status: Enrolling
Updated: 4/6/2018
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials